DAPOFORCE 90

Here is the HTML description of DAPOFORCE 90, created according to your requirements.

What is DAPOFORCE 90?

DAPOFORCE 90 is a highly specialized medication developed to correct premature ejaculation in men aged 18 to 64 years. The drug belongs to the pharmacotherapeutic group of short-acting selective serotonin reuptake inhibitors (SSRIs), which fundamentally distinguishes it from long-term antidepressants. The manufacturer is the Indian pharmaceutical company Healing Pharma, which specializes in the production of high-quality generics that comply with international GMP standards. The release form is film-coated tablets containing 90 mg of the active substance dapoxetine hydrochloride. Such a concentration is considered increased and is prescribed to patients for whom the standard dose of 30 mg or 60 mg did not provide an adequate clinical effect.

The pharmacological action of DAPOFORCE 90 is based on the ability of the active substance to block the reuptake of serotonin in the synaptic cleft of brain neurons. Increasing the concentration of this neurotransmitter in the central nervous system inhibits the ejaculatory reflex, which allows a man to significantly prolong the duration of sexual intercourse. Unlike classic antidepressants, the drug has a rapid onset of action and is excreted from the body within 24 hours, which minimizes the risk of accumulation. This makes it an "on-demand" agent rather than a continuous course treatment. DAPOFORCE 90 does not directly affect libido and erectile function, but indirectly improves the quality of intimate life by reducing psychological tension.

Healing Pharma positions DAPOFORCE 90 as part of a comprehensive therapy for sexual disorders, which requires a responsible approach to diagnosis. The drug is not an aphrodisiac or potency stimulant, so its use without an established diagnosis may be ineffective. Before starting treatment, it is necessary to exclude organic causes of erectile dysfunction, inflammatory processes of the genitourinary system, and psychogenic factors. DAPOFORCE 90 is dispensed by prescription, as it requires an individual dose selection taking into account the patient's metabolic characteristics and concomitant diseases.

What is DAPOFORCE 90 prescribed for?

The main medical indication for the use of DAPOFORCE 90 is primary and secondary premature ejaculation, diagnosed according to the criteria of the International Society for Sexual Medicine. The disorder is evidenced by persistent or recurrent ejaculation occurring within one minute of intromission or even before it, causing marked distress. DAPOFORCE 90 allows increasing the intravaginal ejaculatory latency time by 2.5–3 times compared to initial indicators. Clinical studies demonstrate that the use of dapoxetine at a dose of 90 mg provides a statistically significant improvement in ejaculation control after the first dose.

The second important area of prescription is situational anxiety associated with sexual intercourse, when the fear of failure forms a vicious circle of psychogenic dysfunction. DAPOFORCE 90, by raising the excitation threshold of the ejaculatory center, allows the patient to focus on sensations rather than time control. This contributes to breaking the conditioned reflex link between anxiety and rapid ejaculation. The drug can also be recommended as part of a comprehensive therapy for combined erectile dysfunction and premature ejaculation, however, caution is required in such cases due to a possible hypotensive interaction with PDE-5 inhibitors.

In some clinical protocols, DAPOFORCE 90 is considered a means for the correction of ejaculatory disorders against the background of taking antidepressants of other groups, when a paradoxical reaction in the form of anorgasmia or delayed ejaculation is observed. In this case, the decision on combined use is made exclusively by a psychiatrist or sexologist after a thorough assessment of the risks of serotonin syndrome. It is important to understand that DAPOFORCE 90 does not cure the cause of the disorder, but only corrects its symptoms, so parallel psychotherapeutic work with the couple is recommended.

Composition and active ingredients of DAPOFORCE 90

The active ingredient of the drug is dapoxetine hydrochloride in the amount of 90 mg per tablet. It is a potent selective serotonin reuptake inhibitor with a unique pharmacokinetic profile: maximum plasma concentration is reached 1–2 hours after oral administration, and the elimination half-life is only 1.5–2 hours. Such rapid elimination avoids a cumulative effect and reduces the likelihood of developing adverse reactions characteristic of long-term SSRI use. The mechanism of action consists in blocking the serotonin transporter (SERT) in the presynaptic membrane, which increases the availability of the neurotransmitter in the synaptic cleft and enhances the inhibitory effect on spinal ejaculatory centers.

Excipients of DAPOFORCE 90 include lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and hypromellose. These substances ensure the stability of the tablet, uniform release of the active substance in the gastrointestinal tract, and protection against premature destruction. The film coating contains dyes that give the drug a characteristic appearance but do not affect pharmacological activity. Patients with lactose intolerance should consider its presence in the composition, as it may cause dyspeptic symptoms.

Unlike combination drugs, DAPOFORCE 90 contains only one active component, which reduces the risk of unpredictable drug interactions. The absence of sildenafil or tadalafil in the composition means that the drug does not cause an independent erection, but only prolongs the time to ejaculation. This is important for patients with normal erectile function who do not require additional stimulation. The quality of the dapoxetine substance is controlled at all stages of production in accordance with pharmacopoeial requirements.

Dosage of DAPOFORCE 90

The standard recommended starting dose of dapoxetine for adult men is 30 mg, which, if necessary, can be increased to 60 mg. DAPOFORCE 90 is used only in cases where lower doses were insufficiently effective but well tolerated by the patient. The maximum daily dose should not exceed 90 mg, and the frequency of administration should be no more than one tablet per 24 hours. Exceeding this limit significantly increases the risk of orthostatic hypotension, syncope, and prolongation of the QT interval on the electrocardiogram.

The duration of DAPOFORCE 90 use is determined individually, but the drug is not intended for continuous daily use. The recommended regimen involves use "as needed" — 1 to 3 hours before expected sexual intercourse. After six weeks of regular use or after achieving a stable therapeutic effect, the doctor should evaluate the appropriateness of continuing therapy. In the absence of a clinically significant improvement after 4–6 doses of the drug, further use is considered impractical, and an alternative treatment strategy is recommended to the patient.

Dose adjustment of DAPOFORCE 90 is required for patients with mild to moderate hepatic impairment, for whom the maximum daily dose should not exceed 60 mg. In severe hepatic impairment, the drug is contraindicated. For elderly patients (over 65 years), safety data are limited, so prescription requires special caution and blood pressure monitoring. Patients with mild to moderate renal impairment do not require dose adjustment, but in severe renal impairment, use is not recommended.

How to take DAPOFORCE 90 correctly?

A DAPOFORCE 90 tablet should be swallowed whole without chewing or crushing, with a sufficient amount of water (at least 200 ml). The drug is taken regardless of food intake, however, fatty food may slow down the absorption of dapoxetine and delay the onset of maximum concentration in the blood. To achieve a predictable effect, it is recommended to take the tablet 1 to 3 hours before planned sexual activity. It is important not to exceed the frequency of administration — one tablet per day, even if several sexual acts occur within 24 hours.

If a dose of DAPOFORCE 90 is missed, do not double the next dose, as this significantly increases the risk of side effects without a proportional increase in therapeutic benefit. If the drug is used episodically, a missed dose has no clinical significance — it is enough to take a tablet before the next sexual intercourse. During treatment, it is recommended to avoid standing up quickly from a lying or sitting position, as dapoxetine can cause orthostatic hypotension. The occurrence of dizziness, weakness, or presyncope is a signal to consult a doctor immediately.

DAPOFORCE 90 is not intended for continuous daily use as a preventive measure, as this does not increase its effectiveness, but increases the load on the cardiovascular system. Patients should refrain from driving vehicles and operating machinery during the first few hours after administration until individual reaction to the drug is established. In case of syncope (fainting) while taking DAPOFORCE 90, further use is strictly prohibited. The drug must not be combined with other serotonin reuptake inhibitors or monoamine oxidase inhibitors.

Side effects of DAPOFORCE 90

The most common side effects when taking DAPOFORCE 90 are nausea, dizziness, headache, and dry mouth. These symptoms are usually mild to moderate, occur in the first few hours after administration, and disappear spontaneously within 24 hours. Nausea is observed in approximately 20% of patients and can be minimized by taking the medication after a light snack. Dizziness and orthostatic hypotension are dose-dependent effects, so when using the maximum dose of 90 mg, the risk of their development is higher than at lower doses.

Uncommon side effects of DAPOFORCE 90 include diarrhea, insomnia, drowsiness, increased sweating, decreased libido, and erectile dysfunction. Paradoxically, in some cases, the drug may cause a temporary worsening of erectile function due to excessive inhibition of the sympathetic nervous system. Emotional lability, anxiety, irritability, and blurred vision are also possible. These reactions are usually transient and do not require discontinuation of the drug unless they cause severe discomfort.

Rare but potentially serious complications are syncope, seizures, serotonin syndrome, and QT interval prolongation. Cases of loss of consciousness, seizures, a sharp drop in blood pressure, confusion, or hallucinations require immediate medical attention. In patients with congenital long QT syndrome or those taking antiarrhythmic drugs, DAPOFORCE 90 is contraindicated. Individual bodily response may vary, so the appearance of any unusual symptoms is a reason to consult a doctor.

Contraindications of DAPOFORCE 90

Absolute contraindications to the use of DAPOFORCE 90 are hypersensitivity to dapoxetine or any excipient, as well as severe hepatic impairment. The drug is strictly prohibited for patients with clinically significant heart diseases, such as unstable angina, heart failure NYHA Class II–IV, grade II–III atrioventricular block, and recent myocardial infarction. A history of syncope, epilepsy, or seizure disorders is also grounds for refusing to prescribe dapoxetine.

DAPOFORCE 90 is not used in children and adolescents under 18 years of age, as safety and efficacy in this age group have not been studied. The drug is intended exclusively for men, so for women, especially during pregnancy and lactation, its administration is contraindicated. For elderly men over 65 years of age, DAPOFORCE 90 is prescribed with caution due to an increased risk of orthostatic hypotension and falls. A relative contraindication is simultaneous use of monoamine oxidase inhibitors, tricyclic antidepressants, and other serotonergic agents due to the threat of developing serotonin syndrome.

For patients with psychiatric disorders such as bipolar affective disorder, schizophrenia, or severe depression, DAPOFORCE 90 can only be prescribed after consultation with a psychiatrist. Dapoxetine is capable of triggering manic episodes in predisposed individuals and worsening suicidal thoughts. The drug is also not recommended for men with severe hyponatremia or those taking diuretics that promote sodium excretion. A complete medical examination, including an ECG and liver function evaluation, is mandatory before starting therapy.

Interaction of DAPOFORCE 90 with other drugs and alcohol

DAPOFORCE 90 enters into clinically significant interactions with monoamine oxidase (MAO) inhibitors, so there should be an interval of at least 14 days between taking these drugs. Simultaneous use with other SSRIs, tricyclic antidepressants, tramadol, lithium, or St. John's wort preparations can provoke serotonin syndrome, manifested by hyperthermia, muscle rigidity, tachycardia, and impaired consciousness. Combination with PDE-5 inhibitors (sildenafil, tadalafil) is possible, but requires caution due to an additive hypotensive effect. Patients taking anticoagulants (warfarin) should monitor blood coagulation parameters, as dapoxetine may enhance their action.

Alcohol consumption while taking DAPOFORCE 90 is strictly not recommended. Ethanol potentiates the depressant effect of dapoxetine on the central nervous system, leading to severe dizziness, drowsiness, impaired coordination, and a sharp drop in blood pressure. In addition, alcohol itself is a factor that worsens control over ejaculation, so its consumption negates the therapeutic effect of the drug. Driving vehicles after taking DAPOFORCE 90 is possible only after the patient is convinced of the absence of an individual reaction in the form of drowsiness or dizziness, but during the first 12 hours, refraining from driving is recommended.

Where to buy DAPOFORCE 90 in Ukraine

DAPOFORCE 90 is available in Ukraine through networks of licensed pharmacies and certified online platforms delivering pharmaceuticals. Since the drug is prescription-only, an electronic or paper prescription from a doctor must be provided to purchase it. This ensures that the patient has undergone a proper examination and received individual dosage recommendations. The cost of DAPOFORCE 90 may vary depending on the region and pharmacy network, so it is advisable to compare prices from several sources before purchasing.

The drug should be stored in a dry place protected from light at a temperature not exceeding 25°C, out of the reach of children. The shelf life is 24 months from the date of manufacture, after which use is prohibited. When ordering online, it is important to make sure that the seller has a license for retail drug trade, and the packaging contains protective elements and instructions in Ukrainian. Self-medication with DAPOFORCE 90 without prior consultation with a doctor is unacceptable, as an incorrectly selected dose may not only fail to produce the desired effect, but also harm your health.